Brown Lisle Cummings Inc. Sells 60 Shares of Becton, Dickinson and Company (NYSE:BDX)

Brown Lisle Cummings Inc. reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 738 shares of the medical instruments supplier’s stock after selling 60 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Becton, Dickinson and Company were worth $167,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares in the last quarter. Birch Capital Management LLC grew its position in Becton, Dickinson and Company by 0.4% during the third quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after acquiring an additional 48 shares during the last quarter. Radnor Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after acquiring an additional 48 shares in the last quarter. Finally, Wesbanco Bank Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after acquiring an additional 48 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of analyst reports. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $242.01 on Wednesday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The firm has a market cap of $70.18 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The firm has a 50-day moving average of $230.97 and a 200-day moving average of $233.94.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the business posted $3.42 EPS. The business’s revenue was up 6.9% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.